MX2021004159A - Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para uso en el tratamiento de trastornos del snc. - Google Patents

Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para uso en el tratamiento de trastornos del snc.

Info

Publication number
MX2021004159A
MX2021004159A MX2021004159A MX2021004159A MX2021004159A MX 2021004159 A MX2021004159 A MX 2021004159A MX 2021004159 A MX2021004159 A MX 2021004159A MX 2021004159 A MX2021004159 A MX 2021004159A MX 2021004159 A MX2021004159 A MX 2021004159A
Authority
MX
Mexico
Prior art keywords
treatment
cyclic group
cns disorders
neuroactive steroids
steroids substituted
Prior art date
Application number
MX2021004159A
Other languages
English (en)
Inventor
Francesco G Salituro
Maria Jesus Blanco-Pillado
Marshall Lee Morningstar
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2021004159A publication Critical patent/MX2021004159A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En la presente se provee un compuesto de Fórmula (I) o una sal farmacéuticamente aceptable de este, en donde n, R19, R5, R3a, R6a, R6b, R1, R2a, R2b, R4a, R4b, R7a, R7b, R11a, R11b, R12a, R12b, R17b, R15a, R15b, R16a y R16b se definen en la presente. Asimismo, en la presente se proveen composiciones farmacéuticas que comprenden un compuesto de Fórmula (I) y métodos para usar de los compuestos, por ejemplo, en el tratamiento de trastornos relacionados con el SNC.
MX2021004159A 2018-10-12 2019-10-11 Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para uso en el tratamiento de trastornos del snc. MX2021004159A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862745109P 2018-10-12 2018-10-12
PCT/US2019/055926 WO2020077255A1 (en) 2018-10-12 2019-10-11 Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders

Publications (1)

Publication Number Publication Date
MX2021004159A true MX2021004159A (es) 2021-09-08

Family

ID=68425315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004159A MX2021004159A (es) 2018-10-12 2019-10-11 Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para uso en el tratamiento de trastornos del snc.

Country Status (14)

Country Link
US (2) US11634453B2 (es)
EP (2) EP3864022B1 (es)
JP (2) JP2022504607A (es)
CN (1) CN113166193A (es)
AR (1) AR116695A1 (es)
AU (1) AU2019357040A1 (es)
BR (1) BR112021009428A2 (es)
CA (1) CA3115805A1 (es)
DK (1) DK3864022T3 (es)
ES (1) ES2966055T3 (es)
IL (1) IL282183A (es)
MX (1) MX2021004159A (es)
TW (1) TWI835884B (es)
WO (1) WO2020077255A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2806877T3 (pl) 2012-01-23 2020-06-01 Sage Therapeutics, Inc. Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
LT3224269T (lt) 2014-11-27 2020-07-10 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti cns sutrikimams gydyti
IL302480A (en) 2016-08-23 2023-06-01 Sage Therapeutics Inc 19-NOR C3, 3-Dimuter C21-N-Pyrazolyl Steroid Crystalline
WO2019113494A1 (en) 2017-12-08 2019-06-13 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
DE69518509T2 (de) * 1994-02-14 2001-04-19 Euro Celtique Sa Androstane und pregnane zur allosterischen modulation des gaba-rezeptors
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
CZ292881B6 (cs) 1994-11-23 2003-12-17 Euro-Celtique S.A. Androstanová a pregnanová řada pro allosterickou modulaci GABA receptoru
RU2663665C2 (ru) 2012-12-18 2018-08-08 Вашингтон Юниверсити Нейроактивные 19-алкокси-17-замещенные стероиды и способы лечения с их применением
SG10202009861SA (en) 2014-10-16 2020-11-27 Sage Therapeutics Inc Compositions and methods for treating cns disorders
CA3086189A1 (en) 2017-12-22 2019-06-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
AU2018388408B2 (en) 2017-12-22 2023-12-21 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
CA3090724A1 (en) 2018-02-11 2019-08-15 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
EP3990468A1 (en) 2019-06-27 2022-05-04 Sage Therapeutics, Inc. Compounds for treating cns disorders
TW202114696A (zh) 2019-06-27 2021-04-16 美商賽吉醫療公司 用於治療cns病症之組合物及方法
IL296371A (en) 2020-03-18 2022-11-01 Sage Therapeutics Inc Neuroactive steroids and methods of using them
WO2021262836A1 (en) 2020-06-24 2021-12-30 Sage Therapeutics, Inc. 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof

Also Published As

Publication number Publication date
US20240051987A1 (en) 2024-02-15
TWI835884B (zh) 2024-03-21
JP2024040444A (ja) 2024-03-25
WO2020077255A1 (en) 2020-04-16
ES2966055T3 (es) 2024-04-18
JP2022504607A (ja) 2022-01-13
BR112021009428A2 (pt) 2021-08-31
EP3864022B1 (en) 2023-09-20
IL282183A (en) 2021-05-31
EP4321519A3 (en) 2024-05-01
EP3864022A1 (en) 2021-08-18
TW202027753A (zh) 2020-08-01
US20210340172A1 (en) 2021-11-04
CN113166193A (zh) 2021-07-23
US11634453B2 (en) 2023-04-25
EP4321519A2 (en) 2024-02-14
AR116695A1 (es) 2021-06-02
CA3115805A1 (en) 2020-04-16
DK3864022T3 (da) 2023-12-18
AU2019357040A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
MX2021004159A (es) Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para uso en el tratamiento de trastornos del snc.
MX2021014515A (es) Esteroides neuroactivos y composiciones de estos.
MX2021006618A (es) Esteroides neuroactivos y sus metodos de uso.
MX2021004452A (es) Esteroides neuroactivos no saturados 9(11) y sus métodos de uso.
MX2021015848A (es) Composiciones y métodos para el tratamiento de trastornos del snc.
GEP20237568B (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
EP4331677A3 (en) Methods of treating feline coronavirus infections
MX2023002004A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
WO2021188778A3 (en) Neuroactive steroids and their methods of use
PH12020551256A1 (en) Salts, crystal forms, and production methods thereof
MA40403A (fr) Méthodes de traitement de paramyxovirus
MX2017007814A (es) Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2017012393A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
WO2020115555A3 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
MX2021007069A (es) 3,3-difluoroalilaminas o sales de las mismas y composiciones farmaceuticas que comprenden las mismas.
PH12018501712A1 (en) Methods for treatment and prophylaxis of hiv and aids
PH12019501245A1 (en) Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
MX2022012360A (es) Tratamiento.
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
WO2007087188A3 (en) Taste-masked tablets and granules
MX2021007544A (es) Nuevas formas cristalinas de un compuesto inhibidor de la translocacion de la transcriptasa inversa de nucleosidos.
WO2019240698A3 (en) Oral pharmaceutical composition comprising posaconazole
EP3867222A4 (en) GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF